Acceleron
News/ News/ Sales and Marketing
Merck confirms $11.5bn Acceleron takeover deal
Phil Taylor
Acceleron, cardiovascular disease, M&A, Merck & Co, Reblozyl
0 Comment
News/ News/ Sales and Marketing
Rumour mill says Acceleron is speeding towards $11bn sale
Phil Taylor
Acceleron, Bristol-Myers Squibb, M&A, Reblozyl
0 Comment
EHA21: Study raises BMS’ hopes for Reblozyl in less severe disease
Phil Taylor
Acceleron, beta thalassaemia, Bristol-Myers Squibb, EHA 2021, luspatercept, myelodysplastic syndrome, Reblozyl
0 Comment
Market Access/ News/ News/ News/ Oncology
CHMP backs BMS’ first-in-class anaemia drug Reblozyl
Phil Taylor
Acceleron, beta thalassaemia, Bristol-Myers Squibb, Haematology, luspatercept, myelodysplastic syndrome, Oncology
0 Comment
Celgene scores FDA okay for thalassaemia drug Reblozyl
Phil Taylor
Acceleron, anaemia, beta thalassaemia, Celgene, FDA approval
0 Comment